CML AS PART OF DUAL MALIGNANCIES: POSSIBLE MECHANISMS AND REVIEW OF LITERATURE
(Abstract release date: 05/19/16)
EHA Library. Sahu K. 06/09/16; 134741; PB1841
Dr. Kamal Sahu
Contributions
Contributions
Abstract
Abstract: PB1841
Type: Publication Only
Background
Since the time Imatinib Mesylate has been recommended as standard of care for chronic myeloid leukaemia, the overall survival of CML patients is almost equivalent to general population. Improved survival in CML patients have provided an opportunity to study disease behaviour and its associations in long term basis.
Aims
To study the incidence of secondary malignancies in CML and their outcome
Methods
We reviewed the medical records of all the CML patients treated with Imatinib at PGIMER, Chandigarh, India from 2001-2014.
Results
During a 15 year period (Jan 2001 to Dec 2014), a total of 2183 patients of CML were registered with the adult haematology clinic of PGIMER, Chandigarh of which 1677 patients were included where complete patient details were available. A total of 15 patients were found to have co-existent second malignancy with CML. Four patients had CML as the secondary malignancy. Among 15 patients, three patients had synchronous and 12 had metachronous malignancy. The median age of the patients was 50y (25-66) at the time of diagnosis in this series. Of the 15 patients five were male and rest 10 were female. None of our patients were on 2nd line TKI (Nilotinib and Dasatinib). Two of these 15 patients were in accelerated phase and none in blast phase at the time of diagnosis. History of smoking was present in only one patient who developed bladder cancer and one patient was consumed alcohol in non cirrhogenic doses. None of our patients had history of any carcinogenic exposure. Median duration of imatinib therapy in patients with secondary malignancy is 45.5 months (5 to 130 months). Median duration of follow up was in patients with dual malignancies. Two patients with dual malignancies succumbed to their illness because of blast crisis and one among them was lost to follow up for last 1.5year. None of the patients of CML succumbed to the co-existing malignancy. In patients with CML presenting as primary malignancy (patient no 1-8) the median interval until development of secondary malignancy was 62.3 months (ranged from 8 to 240 months). Whereas, in patients with CML presenting as secondary malignancy the median interval of development of CML was 118.5 months (range 60 to 144 months).None of our patients of co-existent malignancy with CML underwent bone marrow transplantation. Cumulative incidence of second cancer (all categories) in our CML patient cohort is 0.0089. Accordingly, within the limitations of the number of patients which are enrolled in this retrospective analysis, the total number of cases of cancer could be in accordance with the incidence of cancer in the Indian population.
Conclusion
None of our patients of co-existent malignancy with CML underwent bone marrow transplantation. Cumulative incidence of second cancer (all categories) in our CML patient cohort is 0.0089. Accordingly, within the limitations of the number of patients which are enrolled in this retrospective analysis, the total number of cases of cancer could be in accordance with the incidence of cancer in the Indian population.
Session topic: E-poster
Type: Publication Only
Background
Since the time Imatinib Mesylate has been recommended as standard of care for chronic myeloid leukaemia, the overall survival of CML patients is almost equivalent to general population. Improved survival in CML patients have provided an opportunity to study disease behaviour and its associations in long term basis.
Aims
To study the incidence of secondary malignancies in CML and their outcome
Methods
We reviewed the medical records of all the CML patients treated with Imatinib at PGIMER, Chandigarh, India from 2001-2014.
Results
During a 15 year period (Jan 2001 to Dec 2014), a total of 2183 patients of CML were registered with the adult haematology clinic of PGIMER, Chandigarh of which 1677 patients were included where complete patient details were available. A total of 15 patients were found to have co-existent second malignancy with CML. Four patients had CML as the secondary malignancy. Among 15 patients, three patients had synchronous and 12 had metachronous malignancy. The median age of the patients was 50y (25-66) at the time of diagnosis in this series. Of the 15 patients five were male and rest 10 were female. None of our patients were on 2nd line TKI (Nilotinib and Dasatinib). Two of these 15 patients were in accelerated phase and none in blast phase at the time of diagnosis. History of smoking was present in only one patient who developed bladder cancer and one patient was consumed alcohol in non cirrhogenic doses. None of our patients had history of any carcinogenic exposure. Median duration of imatinib therapy in patients with secondary malignancy is 45.5 months (5 to 130 months). Median duration of follow up was in patients with dual malignancies. Two patients with dual malignancies succumbed to their illness because of blast crisis and one among them was lost to follow up for last 1.5year. None of the patients of CML succumbed to the co-existing malignancy. In patients with CML presenting as primary malignancy (patient no 1-8) the median interval until development of secondary malignancy was 62.3 months (ranged from 8 to 240 months). Whereas, in patients with CML presenting as secondary malignancy the median interval of development of CML was 118.5 months (range 60 to 144 months).None of our patients of co-existent malignancy with CML underwent bone marrow transplantation. Cumulative incidence of second cancer (all categories) in our CML patient cohort is 0.0089. Accordingly, within the limitations of the number of patients which are enrolled in this retrospective analysis, the total number of cases of cancer could be in accordance with the incidence of cancer in the Indian population.
Conclusion
None of our patients of co-existent malignancy with CML underwent bone marrow transplantation. Cumulative incidence of second cancer (all categories) in our CML patient cohort is 0.0089. Accordingly, within the limitations of the number of patients which are enrolled in this retrospective analysis, the total number of cases of cancer could be in accordance with the incidence of cancer in the Indian population.
Session topic: E-poster
Abstract: PB1841
Type: Publication Only
Background
Since the time Imatinib Mesylate has been recommended as standard of care for chronic myeloid leukaemia, the overall survival of CML patients is almost equivalent to general population. Improved survival in CML patients have provided an opportunity to study disease behaviour and its associations in long term basis.
Aims
To study the incidence of secondary malignancies in CML and their outcome
Methods
We reviewed the medical records of all the CML patients treated with Imatinib at PGIMER, Chandigarh, India from 2001-2014.
Results
During a 15 year period (Jan 2001 to Dec 2014), a total of 2183 patients of CML were registered with the adult haematology clinic of PGIMER, Chandigarh of which 1677 patients were included where complete patient details were available. A total of 15 patients were found to have co-existent second malignancy with CML. Four patients had CML as the secondary malignancy. Among 15 patients, three patients had synchronous and 12 had metachronous malignancy. The median age of the patients was 50y (25-66) at the time of diagnosis in this series. Of the 15 patients five were male and rest 10 were female. None of our patients were on 2nd line TKI (Nilotinib and Dasatinib). Two of these 15 patients were in accelerated phase and none in blast phase at the time of diagnosis. History of smoking was present in only one patient who developed bladder cancer and one patient was consumed alcohol in non cirrhogenic doses. None of our patients had history of any carcinogenic exposure. Median duration of imatinib therapy in patients with secondary malignancy is 45.5 months (5 to 130 months). Median duration of follow up was in patients with dual malignancies. Two patients with dual malignancies succumbed to their illness because of blast crisis and one among them was lost to follow up for last 1.5year. None of the patients of CML succumbed to the co-existing malignancy. In patients with CML presenting as primary malignancy (patient no 1-8) the median interval until development of secondary malignancy was 62.3 months (ranged from 8 to 240 months). Whereas, in patients with CML presenting as secondary malignancy the median interval of development of CML was 118.5 months (range 60 to 144 months).None of our patients of co-existent malignancy with CML underwent bone marrow transplantation. Cumulative incidence of second cancer (all categories) in our CML patient cohort is 0.0089. Accordingly, within the limitations of the number of patients which are enrolled in this retrospective analysis, the total number of cases of cancer could be in accordance with the incidence of cancer in the Indian population.
Conclusion
None of our patients of co-existent malignancy with CML underwent bone marrow transplantation. Cumulative incidence of second cancer (all categories) in our CML patient cohort is 0.0089. Accordingly, within the limitations of the number of patients which are enrolled in this retrospective analysis, the total number of cases of cancer could be in accordance with the incidence of cancer in the Indian population.
Session topic: E-poster
Type: Publication Only
Background
Since the time Imatinib Mesylate has been recommended as standard of care for chronic myeloid leukaemia, the overall survival of CML patients is almost equivalent to general population. Improved survival in CML patients have provided an opportunity to study disease behaviour and its associations in long term basis.
Aims
To study the incidence of secondary malignancies in CML and their outcome
Methods
We reviewed the medical records of all the CML patients treated with Imatinib at PGIMER, Chandigarh, India from 2001-2014.
Results
During a 15 year period (Jan 2001 to Dec 2014), a total of 2183 patients of CML were registered with the adult haematology clinic of PGIMER, Chandigarh of which 1677 patients were included where complete patient details were available. A total of 15 patients were found to have co-existent second malignancy with CML. Four patients had CML as the secondary malignancy. Among 15 patients, three patients had synchronous and 12 had metachronous malignancy. The median age of the patients was 50y (25-66) at the time of diagnosis in this series. Of the 15 patients five were male and rest 10 were female. None of our patients were on 2nd line TKI (Nilotinib and Dasatinib). Two of these 15 patients were in accelerated phase and none in blast phase at the time of diagnosis. History of smoking was present in only one patient who developed bladder cancer and one patient was consumed alcohol in non cirrhogenic doses. None of our patients had history of any carcinogenic exposure. Median duration of imatinib therapy in patients with secondary malignancy is 45.5 months (5 to 130 months). Median duration of follow up was in patients with dual malignancies. Two patients with dual malignancies succumbed to their illness because of blast crisis and one among them was lost to follow up for last 1.5year. None of the patients of CML succumbed to the co-existing malignancy. In patients with CML presenting as primary malignancy (patient no 1-8) the median interval until development of secondary malignancy was 62.3 months (ranged from 8 to 240 months). Whereas, in patients with CML presenting as secondary malignancy the median interval of development of CML was 118.5 months (range 60 to 144 months).None of our patients of co-existent malignancy with CML underwent bone marrow transplantation. Cumulative incidence of second cancer (all categories) in our CML patient cohort is 0.0089. Accordingly, within the limitations of the number of patients which are enrolled in this retrospective analysis, the total number of cases of cancer could be in accordance with the incidence of cancer in the Indian population.
Conclusion
None of our patients of co-existent malignancy with CML underwent bone marrow transplantation. Cumulative incidence of second cancer (all categories) in our CML patient cohort is 0.0089. Accordingly, within the limitations of the number of patients which are enrolled in this retrospective analysis, the total number of cases of cancer could be in accordance with the incidence of cancer in the Indian population.
Session topic: E-poster
{{ help_message }}
{{filter}}